Jaguar Health
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Pine St Ste 400, San Francisco, Cali...Phone Number
(415) 371-8300Website
jaguar.healthRevenue
$29.5 MillionStock Symbol
JAGXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Jaguar Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Jaguar Health is based in San Francisco, CA.Explore more
Jaguar Health Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jaguar Health your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Jaguar Health recently announced quarterly report
Jaguar Health, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Jaguar Health has new funding data
Check if Jaguar Health has recently received funding, and reach out quickly before it becomes old news!
Check out if Jaguar Health is spiking on competitors!
Product Launch: Get notified when Jaguar Health launches new products
Congratulate Masked Content for being promoted to Masked Content at Jaguar Health
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Jaguar Health had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Jaguar Health as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Jaguar Health is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Jaguar Health is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Jaguar Health.
Jaguar Health financials insights
Gather financial insights about Jaguar Health, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2005
Private Equity
$500K
2010
Private Equity
$3.4M
2011
Unspecified
$3M
Private Equity
$3.1M
2017
Debt
$2M
2025
Multiple Rounds
$6.8M
2026
Stock/Share Issuance
$2M
Stock/Share Issuance
$40.8M
Jaguar Health Tech Stack
A closer look at the technologies used by Jaguar Health
See more technologies
Most Recent Scoops
Project
Jaguar Health has noted that its MVID NDA filing, targeted for mid-2027, is expected to coincide with the availability of Phase II SBS study results, with the MVID development program serving as the CMC manufacturing foundation for the planned regulatory pathway toward crofelemer approval for SBS.
Pharmaceuticals, Clinical Operations
Earnings
recognized license revenues of $16 million from the Future Pak upfront payment and $3 million from the early termination of a buyback option in Q1 2026, and subsequently satisfied the closing conditions required to receive the additional $2 million non-dilutive holdback payment from Future Pak, as announced in August 2026.
Earnings, Finance
Project
Jaguar Health is targeting completion of sufficient patients in the treatment-only extension phase by Q4 2026 to file for Breakthrough Therapy Designation in the United States, which, if granted, could reduce the NDA review period to approximately four months after filing.
Pharmaceuticals, Clinical Operations
Project
Jaguar Health has embarked on an ongoing clinical development path for crofelemer targeting pediatric microvillous inclusion disease (MVID), an ultra-rare disorder with no approved therapies, with a clinical package expected to be finalized by the end of 2026 and an NDA submission targeted for mid-2027.
Product Development, Pharmaceuticals, Clinical Operations
Project
Clinical Operations
Jaguar Health News & Media
Jaguar Health says equity rebuilt above Nasdaq minimum after financing, inventory and ...
Jaguar Health reported its stockholders’ equity exceeded $2.5 million after receiving non-dilutive capital, inventory payments and debt extinguishment gains. Key Highlights: Original SEC Filing: Jaguar Health, Inc. [ JAGX ] - 8-K - Apr. 09, 2026This is an AI-powered summary. It may contain inaccur…Jaguar Health Extends Debt, Defers Royalty Payments; Terminates 48211-Share Warrants
Jaguar Health executed a series of financing actions to improve liquidity and extend maturities. The company amended royalty financings with Uptown Capital and Streeterville Capital, deferring monthly payment start dates to July 1, 2026 and cutting repayment amounts by 10% to $11.13 million and $12…Jaguar Health Secures FDA Grant for Canalevia-CA1 Studies - WebDisclosure
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Jaguar Health
Sign Up For FreeTo access detailed company insights
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants u... Read More
